Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide for Obesity (OSO Study)
NCT05442450Phase 4Unknown
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in obesity, sponsored by Asian Institute of Gastroenterology. Status: unknown.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05442450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442450.